SYNT Stock Overview Engages in the development and marketing of imaging and software solutions for magnetic resonance imaging (MRI) in Sweden and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
SyntheticMR AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for SyntheticMR Historical stock prices Current Share Price SEK 27.70 52 Week High SEK 34.90 52 Week Low SEK 17.30 Beta 0.96 1 Month Change 0% 3 Month Change 1.09% 1 Year Change -13.44% 3 Year Change -40.69% 5 Year Change 6.54% Change since IPO 1,008.00%
Recent News & Updates
SyntheticMR Receives FDA 510(K) Clearance for SyMRI 15 Dec 07
Syntheticmr AB (Publ) Appoints Vedran Beglerbegovic as Acting CEO Dec 04
SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia Oct 29
SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024 Oct 21
SyntheticMR Announces Appointment of Francois Hebert as New President, North America Sep 04
SyntheticMR Receives Regulatory Approval for Symri in Taiwan Aug 19 See more updates
SyntheticMR Receives FDA 510(K) Clearance for SyMRI 15 Dec 07
Syntheticmr AB (Publ) Appoints Vedran Beglerbegovic as Acting CEO Dec 04
SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia Oct 29
SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024 Oct 21
SyntheticMR Announces Appointment of Francois Hebert as New President, North America Sep 04
SyntheticMR Receives Regulatory Approval for Symri in Taiwan Aug 19 SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024
SyntheticMR AB (publ) Announces Board Changes May 23
SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024 Apr 23
SyntheticMR AB (publ), Annual General Meeting, May 21, 2024 Apr 21
SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D Mar 30
SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024 Jan 22
Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now? Dec 20
SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking Dec 18
SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance Nov 22
SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting Nov 18
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 16
SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023 Oct 12
What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate? Sep 21
Second quarter 2023 earnings: EPS exceeds analyst expectations Aug 23
Now 22% undervalued after recent price drop Aug 04
SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023 Jul 24
Now 20% undervalued after recent price drop Jul 20
SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11 Jun 17
SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow Jun 14
SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea Jun 01
Consensus EPS estimates fall by 28% May 30
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 24
Full year 2022 earnings: EPS misses analyst expectations Apr 15
Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital Mar 18
Consensus EPS estimates fall by 20% Feb 27
Consensus EPS estimates fall by 20% Feb 22
Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021) Feb 16
Now 24% undervalued after recent price drop Feb 15 SyntheticMR AB (publ), Annual General Meeting, May 23, 2023
Consensus EPS estimates fall by 17% Feb 01
Now 21% undervalued after recent price drop Jan 27
SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023 Jan 17
Now 20% undervalued after recent price drop Dec 02
There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital Nov 29
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 18
No independent directors Nov 16
Now 21% undervalued after recent price drop Nov 05
SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate Oct 29
SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022 Oct 18
SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil Oct 08
Consensus EPS estimates increase by 18% Sep 22
SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia Sep 07
SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia Sep 06
Consensus EPS estimates fall by 14% Sep 02
Consensus EPS estimates increase by 16% Aug 30
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 23
What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate? Aug 06
SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022 Jul 25
SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times Jul 14
Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board Jul 06
SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers May 31
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Consensus revenue estimates fall by 19% May 04
Price target decreased to kr36.00 May 03
No independent directors Apr 27
Full year 2021 earnings: EPS misses analyst expectations Apr 12
SyntheticMR AB (publ), Annual General Meeting, May 10, 2022 Apr 09
SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022 Apr 07
Now 24% undervalued after recent price drop Apr 06
Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022 Apr 06
Now 21% undervalued after recent price drop Mar 08
Full year 2021 earnings: EPS misses analyst expectations Feb 24
Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching Feb 23
Now 21% undervalued after recent price drop Feb 08
A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT) Jan 27
Third quarter 2021 earnings released: EPS kr0.06 (vs kr0.004 loss in 3Q 2020) Nov 12
Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now? Nov 10
SyntheticMR Signs Global Agreement with Philips to include SyntheticMR's Solution in Third Party Product Catalogue Sep 08
Second quarter 2021 earnings released Jul 14
Consensus EPS estimates fall to kr0.32 Jul 11
Price target decreased to kr44.00 Jul 09
Director recently sold kr4.0m worth of stock Jun 18
Director recently bought kr75k worth of stock Jun 10
Consensus EPS estimates fall to kr4.49 May 18
First quarter 2021 earnings released: EPS kr0.67 (vs kr0.19 in 1Q 2020) May 13
SyntheticMR AB (publ) Approves No Dividend Will Be Paid for the Full Year 2020 May 12 SyntheticMR AB (publ) Appoints Johanna Norén as CFO
Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares Mar 09
Full year 2020 earnings released: EPS kr0.11 (vs kr0.92 in FY 2019) Feb 20
Revenue and earnings beat expectations Feb 20
Syntheticmr AB (Publ) Proposes No Dividend Will Be Paid for the Full Year 2020 Feb 18
Price target raised to kr450 Feb 16
What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own? Feb 11
New 90-day high: kr390 Feb 10
Syntheticmr AB Partners with United Imaging Feb 10
New 90-day high: kr354 Jan 18
SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings Dec 03
SyntheticMR Announces Submission of 510(K) to FDA for Quantitative MSK MRI Package Nov 18
Revenue and earnings miss expectations Nov 13 Shareholder Returns SYNT SE Healthcare Services SE Market 7D 0% -3.3% -2.2% 1Y -13.4% 59.7% 6.1%
See full shareholder returns
Return vs Market: SYNT underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility Is SYNT's price volatile compared to industry and market? SYNT volatility SYNT Average Weekly Movement n/a Healthcare Services Industry Average Movement 5.7% Market Average Movement 5.6% 10% most volatile stocks in SE Market 11.3% 10% least volatile stocks in SE Market 3.2%
Stable Share Price: SYNT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYNT's volatility change over the past year.
About the Company SyntheticMR AB (publ) engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific. Its SyMRI delivers various contrast images, biomarker segmentations, and quantitative data with a single MR sequence. The company also offers SyMRI NEURO includes contrast weighted images, as well as biomarker segmentation, volumetric measurements of brain tissues and parametric maps that provide objective decision support for the diagnosis and follow-up of patients; SyMRI MSK works on a range of anatomies, and provides quantitative T1, T2, and PD maps, as well as multiple contrast-weighted images; and MAGiC, a customer-specific version of SyMRI IMAGE.
Show more SyntheticMR AB (publ) Fundamentals Summary How do SyntheticMR's earnings and revenue compare to its market cap? SYNT fundamental statistics Market cap SEK 1.15b Earnings (TTM ) SEK 10.01m Revenue (TTM ) SEK 94.37m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SYNT income statement (TTM ) Revenue SEK 94.37m Cost of Revenue SEK 30.33m Gross Profit SEK 64.05m Other Expenses SEK 54.03m Earnings SEK 10.01m
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 21, 2024
Earnings per share (EPS) 0.24 Gross Margin 67.86% Net Profit Margin 10.61% Debt/Equity Ratio 0%
How did SYNT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/04/29 00:00 End of Day Share Price 2024/01/31 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SyntheticMR AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Simon Larsson Danske Bank Christian Lee Pareto Securities
Show 0 more analysts 
